# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k073072   
B. Purpose for Submission: New Submission   
C. Measurand: high-density lipoprotein cholesterol (HDL Cholesterol)   
D. Type of Test: Quantitative colorimetric   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Names: Dimension AHDL Flex Reagent Cartridge

# G. Regulatory Information:

1. Regulation section: 21CFR Sec. 862.1475-Lipoprotein test system.

2. Classification: Class I, meets the limits to exemption under 862.9 (c) (4)

3. Product code: JHM - Colorimetric Method, Lipoproteins

4. Panel: Chemistry (75)

# H. Intended Use:

1. Intended use(s): See Indication(s) for use below   
2. Indication(s) for use: The AHDL method is an in vitro diagnostic test for the quantitative measurement of high-density lipoprotein cholesterol (HDL-C) in human serum and plasma on the Dimension $^ \mathrm { \textregistered }$ clinical chemistry system. Measurements of HDL-C are used as an aid in the diagnosis of lipid disorders (such as diabetes mellitus), various liver and renal diseases and in the assessment of risk for atherosclerosis and cardiovascular disease.   
3. Special conditions for use statement(s): For prescription use.   
4. Special instrument requirements: Dimension $^ \mathrm { \textregistered }$ clinical chemistry system

# I. Device Description:

# Reagents

<table><tr><td>Wells</td><td>Form</td><td>Ingredient</td><td>Concentration</td><td>Source</td></tr><tr><td>1,2,3</td><td>Liquid</td><td>HEPES Buffer</td><td colspan="2">10.07 mmol/L, pH 7.4</td></tr><tr><td colspan="2">Reagent 1</td><td>2-(N-cyclohexylamino)- ethanesulfonic acid</td><td colspan="2">96.95 mmol/L</td></tr><tr><td rowspan="7">4 Reagent 2 5,6</td><td rowspan="7">Liquid</td><td>Dextran Sulfate Magnesium Nitrate Hexahydrate</td><td colspan="2">1.5 g/L ≥11.7 mmol/L</td></tr><tr><td>N-(2-hydroxy-3-sulfopropyl)- 3, 5-dimethoxyaniline Ascorbate Oxidase</td><td>0.96 mmol/L ≥50 μkat/L</td><td>bacterial</td></tr><tr><td>Peroxidase Preservative</td><td>≥ 16.7 μkat/L</td><td>horseradish</td></tr><tr><td>HEPES Buffer</td><td>10.07 mmol/L, pH 7.0</td><td></td></tr><tr><td>PEG-Cholesterol Esterase</td><td>≥ 3.33 μkat/L</td><td>bacterial</td></tr><tr><td>PEG-Cholesterol Oxidase</td><td>≥ 127 μkat/L</td><td>bacterial</td></tr><tr><td>Peroxidase</td><td>≥ 333 μkat/L</td><td>horseradish</td></tr><tr><td>Liquid</td><td></td><td></td><td></td></tr><tr><td>Preservative NaOH</td><td>4-Amino-Antipyrine</td><td>2.46 mmol/L</td><td></td></tr></table>

# J. Substantial Equivalence Information:

1. Predicate device name(s): Dimension $^ \mathrm { \textregistered }$ AHDL Flex $^ \mathrm { \textregistered }$ reagent cartridge   
2. Predicate 510(k) number(s): k032798   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The AHDL method is an in vitrodiagnostic test for the quantitativemeasurement of high-densitylipoprotein cholesterol (HDL-C) inhuman serum and plasma on theDimension® clinical chemistrysystem. Measurements of HDL-Care used as an aid in the diagnosisof lipid disorders (such as diabetesmellitus), various liver and renaldiseases and in the assessment ofrisk for atherosclerosis andcardiovascular disease.</td><td rowspan=1 colspan=1>The AHDL method for theDimension® clinical chemistrysystem is an in vitrodiagnostictest intended toquantitativelymeasure high-density lipoproteincholesterol (HDL-C) inhumanserum and plasma.     HDL-Cmeasurements are used as an aidin the diagnosis of lipid disorders</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human Serum or Plasma</td><td rowspan=1 colspan=1>Human Serum or Plasma</td></tr><tr><td rowspan=1 colspan=1>Sample Size</td><td rowspan=1 colspan=1>3 uL</td><td rowspan=1 colspan=1>3 uL</td></tr><tr><td rowspan=1 colspan=1>Measurementmethod</td><td rowspan=1 colspan=1>PEG HDL-C (polyethylenemodified)</td><td rowspan=1 colspan=1>Accelerator Selective DetergentMethodology</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>3-150 mg/dL</td><td rowspan=1 colspan=1>3-150 mg/dL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

“Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable - Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff “- 4/25/2006

CLSI - Method Comparison and Bias Estimation Using Patient Samples - EP09-A2 CLSI - Evaluation of Precision Performance of Clinical Chemistry Devices - EP05-A2 CLSI - Interference Testing in Clinical Chemistry - EP07-A2 CLSI - Protocols for Determination of Limits of Detection and Limits of Quantitation - EP17-A • Cholesterol Reference Method Laboratory Network (CRMLN) Certification

# L. Test Principle:

The AHDL assay measures HDL cholesterol levels directly without the need for sample pretreatment or specialized centrifugation steps, using a two reagent format. In the first reaction, chylomicrons, VLDL and LDL form water soluble complexes with dextran sulfate in the presence of magnesium sulfate. These complexes are resistant to the polyethylene glycol (PEG)-modified cholesterol esterase and cholesterol oxidase that react with HDL cholesterol. In the presence of oxygen, the HDL cholesterol is oxidized to $\Delta 4$ -cholestenone and hydrogen peroxide. The generated hydrogen peroxide then reacts with 4-aminoantipyrine and sodium N-(2- hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline (HSDA) in the presence of peroxidase to form a colored dye that is measured using a bichromatic $( 6 0 0 / 7 0 0 \mathrm { n m } )$ endpoint technique. The color intensity of the dye is directly proportional to the serum HDL-C concentration.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>With-in Lab</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Bio-Rad</td><td rowspan=1 colspan=5>Bio-Rad Liquid Unassayed Multiqual</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=6>Serum Pools</td></tr><tr><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.1</td></tr><tr><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>92</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.8</td></tr></table>

The reproducibility testing was conducted in accordance with the CLSI/NCCLS Approved Guideline for User Evaluation of Precision Performance of Clinical Chemistry Devices EP5-A2. For each test level, a

single test from two independent cups was analyzed twice per day.

# b. Linearity/assay reportable range:

The Dimension AHDL method demonstrated visual and statistical linearity across the claimed assay range of 3 to $1 5 0 ~ \mathrm { m g / d L }$ . The Dimension AHDL method is linear up to and above the level 3 calibrator $\left( > 1 5 0 \ : \mathrm { m g / d L } \right)$ .

Linearity was evaluated by comparing observed versus expected values obtained with the Dimension $^ \mathrm { \textregistered }$ AHDL method using a series of samples. The samples were prepared by taking the high level calibrator diluted across the expected range with the zero level calibrator.

<table><tr><td rowspan=2 colspan=1>TheoreticalHDL-C(mg/dL)</td><td rowspan=2 colspan=1>MeasuredHDL-C(mg/dL)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>PercentRecovery</td></tr><tr><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.88</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>5.65</td><td rowspan=1 colspan=1>5.53</td><td rowspan=1 colspan=1>97.96</td></tr><tr><td rowspan=1 colspan=1>11.31</td><td rowspan=1 colspan=1>10.93</td><td rowspan=1 colspan=1>96.68</td></tr><tr><td rowspan=1 colspan=1>22.61</td><td rowspan=1 colspan=1>21.91</td><td rowspan=1 colspan=1>96.92</td></tr><tr><td rowspan=1 colspan=1>45.22</td><td rowspan=1 colspan=1>47.02</td><td rowspan=1 colspan=1>103.97</td></tr><tr><td rowspan=1 colspan=1>90.44</td><td rowspan=1 colspan=1>92.70</td><td rowspan=1 colspan=1>102.50</td></tr><tr><td rowspan=1 colspan=1>135.65</td><td rowspan=1 colspan=1>135.56</td><td rowspan=1 colspan=1>99.94</td></tr><tr><td rowspan=1 colspan=1>180.87</td><td rowspan=1 colspan=1>180.87</td><td rowspan=1 colspan=1>100.00</td></tr></table>

![](images/84e8eba47cb0019566bea4741e8487d68b188e253e014416985b3127eec2f536.jpg)

c. Traceability, Stability, Expected values (controls, calibrators, or methods): This method has been evaluated by and met the certification acceptance criteria of the Cholesterol Reference Method Laboratory Network (CRMLN).

The calibrator was cleared under k983850

Controls are not part of this submission nor does the applicant recommend any particular commercially available quality control material.

# d. Detection limit:

Limit of Detection: $3 \mathrm { m g / d L }$

The limit of detection represents the lowest concentration of high density lipoprotein cholesterol that can be detected with at least $9 5 \%$ probability. CLSI/NCCLS EP17-A, Protocols for Determination of Limits of Detection and Limits of Quantitation, was followed using 60 replicate determinations at two concentration levels to determine the Limit of Detection.

# e. Analytical specificity:

The AHDL method was evaluated for interference according to CLSI EP7- A2.

Bias was defined as the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding $10 \%$ was considered interference.

<table><tr><td>Substance Tested</td><td>Substance Concentration</td><td>HDL Cholesterol mg/dL</td><td>Bias %</td></tr><tr><td>Hemoglobin</td><td>Hemoglobin (monomer)</td><td>37</td><td>&lt; 10%</td></tr><tr><td>(hemolysate)</td><td>1000 mg/dL</td><td></td><td></td></tr><tr><td>Bilirubin (unconjugated)</td><td>80 mg/dL</td><td>43 43</td><td>&lt; 10% &lt; 10%</td></tr><tr><td>Bilirubin (conjugated)</td><td>60 mg/dL</td><td>37</td><td>&lt; 10%</td></tr><tr><td>Intralipid</td><td>1000 mg/dL</td><td></td><td></td></tr></table>

f. Assay cut-off: Not Applicable

2. Comparison studies:

a. Method comparison with predicate device:

Method comparison testing was conducted following CLSI Approved Guideline for Method Comparison and Bias Estimation Using Patient Samples; EP9-A2. A total of 134 serum samples were analyzed in parallel for new AHDL and current AHDL on a Dimension $^ \mathrm { \textregistered }$ clinical chemistry analyzer. Seven of the 134 samples were prepared by adding concentrated high density lipoprotein from human serum into normal human serum.

Data were analyzed by least squares linear regression analysis. A subset of the samples with HDL-C concentrations $< 6 0 ~ \mathrm { m g / d L }$ was also analyzed separately.

<table><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept(mg/dL)</td><td rowspan=1 colspan=1>r</td><td rowspan=1 colspan=1>Sy,x</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Sample Range(mg/dL)</td></tr><tr><td rowspan=1 colspan=1>1.04 ± 0.01</td><td rowspan=1 colspan=1>-3.9±0.5</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.77</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>4-131</td></tr><tr><td rowspan=1 colspan=1>0.99 ± 0.02</td><td rowspan=1 colspan=1>-2.5 ± 0.8</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>2.53</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>4-59</td></tr></table>

# b. Matrix comparison:

Comparison of sixty nine matched serum and lithium heparin plasma samples on the Dimension $^ \mathrm { \textregistered }$ system and sixty nine matched serum and sodium heparin plasma samples gave the following linear regression statistics:

<table><tr><td>Serum Vs.</td><td>Slope</td><td>Intercept mg/dL</td><td>Correlation Coefficient</td><td></td></tr><tr><td>Lithium Heparin</td><td>1.00</td><td>0.74</td><td>1.00</td><td>n 69</td></tr><tr><td>Sodium Heparin</td><td>1.01</td><td>0.40</td><td>1.00</td><td>69</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable

c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range: The National Cholesterol Education Program Adult Treatment Panel III (NCEPATP III) provides the following classifications of HDL-C concentrations:

$\mathrm { H D L } < 4 0 ~ \mathrm { m g / d L }$ - Low HDL Cholesterol HDL ≥ 60 mg/dL - High HDL Cholesterol

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.